Creating an affordable treatment for drug-resistant tuberculosis in children
Official title: Phase II: Development of Low-Cost, Shelf-Stable Treatment for Tuberculosis
Funded at Via Therapeutics, LLC · NIH-10935742 · Data updated 2026-11-12
This study is working on a new, affordable medicine for kids with a tough type of tuberculosis that doesn't respond to standard treatment, making it easier for them to get the help they need.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Via Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Austin, United States) |
| Project start | September 15, 2023 |
| Project end | September 14, 2026 |
| Funding year | 2023 |
| Award (this year) | $1,468,122 |
| NIH project number | 75N93023C00060-0-9999-1 |
| Project ID | NIH-10935742 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are pediatric patients diagnosed with rifampicin-resistant pulmonary tuberculosis.
✕Less likely to help
Patients who do not have rifampicin-resistant tuberculosis or who are adults may not benefit from this research.
What this research studies
This research focuses on developing a low-cost and shelf-stable drug formulation specifically designed to treat rifampicin-resistant pulmonary tuberculosis in children. The approach involves creating a medication that is easy to administer, making it more accessible for pediatric patients who suffer from this serious condition. The research will include testing the effectiveness and safety of this new treatment in clinical settings, aiming to improve outcomes for young patients affected by tuberculosis.
Why it matters
Potential benefit: If successful, this research could provide a more affordable and effective treatment option for children suffering from drug-resistant tuberculosis.
How similar studies have gone: Other research has shown promise in developing new treatments for tuberculosis, but this specific approach targeting pediatric patients with drug resistance is relatively novel.
Where this research is happening
-
Via Therapeutics, LLC
Austin, United States Active
Researchers
- Principal investigator: Warnken, Zachary — Via Therapeutics, LLC
- Study coordinator: Warnken, Zachary
Related research
Other NIH-funded projects on the same topics.
-
Coronary disease and immune activation in people with HIV and tuberculosis coinfection
This research looks at how having HIV and latent tuberculosis together might raise the risk of heart disease, and what immune changes are involved.
-
Pulmonary rehabilitation to reduce breathing problems after tuberculosis
A program of guided exercise and breathing training to help adults who have recovered from TB breathe better and feel healthier.
-
Pulmonary rehab to reduce breathing troubles after TB
A program of pulmonary rehabilitation is being studied to help adults who have completed TB treatment avoid ongoing lung problems and improve daily breathing.
-
Air pollution and tuberculosis spread in Kampala, Uganda
This project looks at whether dirty air from PM2.5 particles makes tuberculosis more likely to spread within urban slum households in Kampala, Uganda.
-
Air pollution and TB spread in Ugandan urban slums
This project explores whether exposure to air pollution makes tuberculosis more likely to spread within households in a crowded Ugandan slum.
-
Air pollution and TB transmission in Kampala’s urban slums
This project looks at whether air pollution from PM2.5 makes tuberculosis spread more easily from infected people to their neighbors in urban slums of Kampala, Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.